Promotions & Moves

CorMedix Appoints CFO

Matt David, M.D. has more than 15 years of experience in finance as a healthcare investment banker and earlier as an equity analyst covering the pharma sector

By: Contract Pharma

Contract Pharma Staff

CorMedix Inc., a biopharmaceutical company focused on therapeutics for the prevention and treatment of infectious and inflammatory disease, has appointed Matt David, M.D. as Executive Vice President and Chief Financial Officer.

Dr. David was most recently Head of Strategy at Ovid Therapeutics, a Nasdaq-listed biopharmaceutical company focused on rare neurological diseases. In addition to his recent experience in industry, Dr. David has more than 15 years of experience in finance as a healthcare investment banker and earlier as an equity analyst covering the pharma sector.

“I am pleased that Matt has agreed to join the Company at this most exciting time,” said Khoso Baluch, CorMedix Chief Executive Officer. “With his medical background and his significant experience in healthcare capital markets and strategy, he will fill an important role as we continue our preparations to commercialize Neutrolin, whether on our own or with a strategic or commercial partner.”

“I am thrilled to be joining CorMedix at such an exciting time for the Company,” commented Dr. David. “As Neutrolin approaches a potential regulatory approval later this year, the Company will face a range of strategic decisions all aimed at bringing Neutrolin to patients who can benefit from it as expeditiously as possible. I am excited by the prospects of this novel product in the substantial hemodialysis market and look forward to working with the broader CorMedix team.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters